DPP4 and neoplasm: This is the first finding that the serum sCD26/DPP4 titer variation in the early phase of treatment with the humanized anti-CD26 antibody YS110 may be a predictive biomarker for anti-tumor activity for patients with CD26+ cancers including MM.